AI
MRVI icon

Atria Investments’s Maravai LifeSciences MRVI Stock Holding History

Atria Investments’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,558
Closed -$57.5K – 1971
2024
Q4 		$57.5K Buy
+10,558
New +$67.9K ﹤0.01% 1840

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atria Investments's MRVI Position: Q1 2025 in Review

Atria Investments sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 10,558 shares — an estimated $57.5K sold.

Atria Investments first reported a position in MRVI in Q4 2024 and held it in 1 quarter. The position peaked at $57.5K in Q4 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Atria Investments reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Atria Investments sold 10,558 Maravai LifeSciences shares in Q1 2025, an estimated $57.5K.
  • Atria Investments first reported a position in Maravai LifeSciences in Q4 2024 and held it in 1 quarter.
  • Atria Investments's Maravai LifeSciences position peaked at $57.5K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Atria Investments's 13F filing for Q1 2025, filed 6 May 2025.